{
    "nct_id": "NCT05159700",
    "official_title": "A Phase I, First-In-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors",
    "inclusion_criteria": "* Histologically or cytologically confirmed locally advanced (unresectable) or metastatic r/r solid tumors for which no standard therapy is available or for whom standard therapy is considered unsuitable or intolerable.\n* Male or non-pregnant, non-lactating female subjects age â‰¥18 years.\n* ECOG Performance Status 0~2.\n* Has at least 1 measurable lesion as defined by RECIST 1.1 criteria .\n* Life expectancy of >3 months, in the opinion of the Investigator.\n* Able to take oral medications and willing to record daily adherence to investigational product.\n* Adequate hematologic parameters unless clearly due to the disease under study.\n* Adequate renal and hepatic function\n* Able to understand and willing to sign a written informed consent form.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of another malignancy\n* Known symptomatic brain metastases requiring >10 mg/day of prednisolone.\n* Significant cardiovascular disease\n* Known active HBV, HCV, AIDS-related illness.\n* Has received a live vaccine within 30 days\n* History of active autoimmune disorders or ongoing immunosuppressive therapy.\n* Receiving concurrent anti-cancer therapy, investigational product, strong inhibitors or inducers of cytochrome P450 3A (CYP3A) .\n* Prior treatment with hematopoietic progenitor kinase 1 (HPK1) inhibitors.",
    "miscellaneous_criteria": "Key"
}